SciSparc Ltd. SPRC announced that Clearmind Medicine Inc. CMNDF CMND CWYHas filed a provisional patent application related to metabolic syndromes including obesityregarding the company’s cooperation with Clearmind.
The patent filing is the third of the collaboration, each relating to SciSparc’s proprietary combination palmitoylethanolamide (PEA), the active ingredient of its own CannAmid (used to treat obesity and associated metabolic disorders) and Clearmind’s MEAIa novel proprietary psychedelic treatment for various addictions based on research at the Hebrew University.
“Our collaboration with Clearmind is focused on treating various addictions and binge eating, taking advantage of our technology and that of Clearmind. Obesity, overweight and binge eating are among the top health problems of the past decade and are linked to addictive behaviors, yet treatment options available on the market are very limited,” he said Oz Adler, CEO of SciSparc. “We believe the combination of MEAI with SciSparc’s CannAmide could provide a great opportunity to treat these conditions.”
About SciSparc
SciSparc Ltd. is a specialty clinical stage pharmaceutical company. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on Cannabinoid Medicines. With this focus, the Company is currently engaged in the following THC and/or non-psychoactive CBD-based drug development programs: SCI-110 for the treatment of Tourette’s Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for pain management; and SCI-210 for the treatment of autism spectrum disorders and status epilepticus.
Photo: Benzinga; Sources: courtesy of Jarmoluk and Lindsayfox via Pixabay
Similar news
SciSparc acquires one of Amazon’s top-selling hemp-based dietary supplements, cosmetics and products
Psychedelics-based cocaine addiction treatment study with positive results. We know this
[ad_2]
Source story